AtaiBeckley: BPL-003 Phase 3 Momentum Keeps Me Bullish

AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. BPL-003 posted encouraging depression data and has the FDA's Breakthrough Therapy Designation. We also know BPL-003 is expected to enter Phase 3 in Q2 2026. VLS-01 and EMP-01 add pipeline depth.